Health Technologies

Time to boost cancer vaccine work, say UK researchers

UK oncology researchers are calling for a boost to cancer vaccine research, which holds the potential to revolutionise cancer treatment.

Cancer vaccines leverage neoantigens to activate the immune system against tumours, offering a personalised approach to combat cancer. This transformative potential is particularly significant in light of recent advancements in oncology, including immune checkpoint inhibitors and CAR-T cell therapies, say the researchers.

The backdrop of the Covid-19 pandemic has also demonstrated how it is possible to develop vaccines swiftly, setting the stage for a strategic shift towards cancer vaccine trials.

The UK, with its substantial contributions to both vaccine development and distribution during the pandemic, is uniquely well-positioned to lead this charge, the team suggest.

Lead author of the paper calling for more research, Lennard Lee, associate professor of Cancer Vaccines at the University of Oxford and clinical advisor on the NHS Cancer Vaccine Launchpad, said: “A central challenge for the UK in developing cancer vaccines lies in harnessing national infrastructure, particularly the country’s healthcare system, to facilitate efficient trials.

“This will require careful coordination and allocation of resources to support local trial delivery centres across the country.

“Yet the UK is a scientific powerhouse – meaning that with continued investment and effort, there is no reason why the UK shouldn’t be a pioneer in cancer vaccine development.”

The researchers also offered four key recommendations for how the UK can best level-up in cancer vaccine research.

Firstly, they recommend leveraging Covid-19 vaccine success, suggesting that insights can be drawn from the rapid development and deployment of Covid-19 vaccines. Processes were streamlined, pragmatism prevailed over perfections and groups were able to make timely decisions, and the researchers say that cancer vaccine trials should be delivered in a similar fashion.

Secondly, they suggest creating shared missions. As there is a multitude of pharmaceutical partners with new cancer vaccine technologies across many different subtypes of cancers, long-term partnerships between trialists, sites, industry, healthcare leads and patient groups can forge the path for continual iterative improvement of cancer vaccine technologies.

Thirdly, they suggest modernising trial infrastructure. Cancer vaccines require effective trials infrastructure with seamless integration of genomic data across different platforms and institutions. Trial teams and infrastructure should receive investments to upgrade and be made as effective as possible.

Finally, the researchers suggest engaging the public and trialists, noting that greater attempts can be made at fostering effective public awareness. This includes understanding the potential opportunities and limitations of cancer vaccine technology. They suggest this effort should aim to garner support and increase the momentum of clinical trials at small as well as large cancer centres.

Avatar

admin

About Author

You may also like

Health Technologies

Accelerating Strategies Around Internet of Medical Things Devices

  • December 22, 2022
IoMT Device Integration with the Electronic Health Record Is Growing By their nature, IoMT devices are integrated into healthcare organizations’
Health Technologies

3 Health Tech Trends to Watch in 2023

Highmark Health also uses network access control technology to ensure computers are registered and allowed to join the network. The